-
Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to Age: Insights From DAPA-HFMartinez FA, Serenelli M, Nicolau JC et al. -
Heart Failure and Atrial Fibrillation, Like Fire and FuryMA Carlisle, M Fudim, AD DeVore et al.
-
Dapagliflozin and Cardiovascular Outcomes in Type 2 DiabetesSD Wiviott，I Raz，DECLARE–TIMI 58 Investigators.
-
Sex- and Race-Related Differences in Characteristics and Outcomes of Hospitalizations for Heart Failure With Preserved Ejection FractionGoyal P, Paul T, Almarzooq ZI et al.
-
Cardiac resynchronization therapy with a defibrillator (CRTd) in failing heart patients with type 2 diabetes mellitus and treated by glucagon-like peptide 1 receptor agonists (GLP-1 RA) therapy vs. conventional hypoglycemic drugs: arrhythmic burden, hospitalizations for heart failure, and CRTd responders rateSardu C, Paolisso P, Sacra C et al.
-
How to diagnose heart failure with preserved ejection fraction: the HFA-PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC)Pieske B Tschöpe C, de Boer RA et al.
-
Association of Left Ventricular Systolic Function With Incident Heart Failure in Late LifeAMR Jensen, R Zierath, B Claggett et al.
-
Dapagliflozin in Patients with Heart Failure and Reduced Ejection FractionMcMurray JJV, SD Solomon, DAPA-HF Committees and Investigators.
http://www.cbsmd.cn Contact us by cbs@cbsmd.cn
Copyright ⓒ CBSMD Nanjing China. All rights reserved.
